27
Apr
2008
02
Apr
2007
Orqis (Lake Forest, CA) is developing devices to prevent or reverse the underlying disease progression of congestive heart failure has closed a $37.4M Series D financing. New investors include Wasatch Advisors, Cross Creek Capital and the Omega Fund along with Boston Scientific and Lighthouse Capital Partners.
02
Apr
2007
Posted in I - Series B, Q - 2Q07, R - WEST, X - Cardiology, X - Inflammation
Amira Pharmaceuticals (San Diego, CA) drug company focused on inflammatory respitory and cardiovascular disease solutions via the leukotriene and TNF? pathways closed a $25M Series B financing. The deal was led by Novo AS and joined by Avalon Ventures, Prospect Venture Partners and Versant Ventures.
06
Mar
2007
30
Jan
2007
Posted in I - Series B, Q - 1Q07, R - WEST, X - Cardiology, XXX - My Rants
Symphony Medical (Laguna Hills, CA) develops proprietary biopolymer and cellular-based biologic therapies to effectively treat chronic and post-operative atrial fibrillation and other cardiac conduction abnormalities, has raised $5M, bringing the aggregate investment in all rounds into Symphony Medical to $17 million. The only participants in the round were Domain Associates, Johnson & Johnson Development Corp., [...]
17
Jan
2007
Symphony Medical (Laguna Hills, CA) develops proprietary biopolymer and cellular-based biologic therapies to effectively treat chronic and post-operative atrial fibrillation and other cardiac conduction abnormalities, has raised another $11.2M in Series B funding. Participants include Domain Associates, Johnson & Johnson Development Corp., Morgenthaler Ventures, Triathlon Medical Ventures and Guidant Compass Group.